TheraRadar
← Back
Data updated: Jun 28, 2026

SUMITOMO PHARMA AM

Specialty
OncologyNeurologyRespiratory Execution: Excellent

SUMITOMO PHARMA AM is a specialty pharmaceutical company focused on Oncology, Neurology, Respiratory. Key products include MYFEMBREE.

2013
Since
6
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
4 Small Molecules

FDA Novel Drug Designations

(2020)
2 Novel 1 Priority Review
See 2 novel approvals →
2020 GEMTESA (VIBEGRON)
2020 ORGOVYX (RELUGOLIX) Priority Review

SUMITOMO PHARMA AM at a Glance

  • Strong track record with 85% execution quality across 131 trials
  • Fast trial execution (23 months median completion)

SUMITOMO PHARMA AM's Key Drugs

SUMITOMO PHARMA AM's core commercial portfolio centers on MYFEMBREE, GEMTESA, APTIOM, spanning Oncology and Neurology — its most strategically important drugs approved in the last 15 years.

MYFEMBREE
Women's Health

Heavy Menstrual Bleeding

Estrogen Receptor Approved 2021
GEMTESA
Urology

Overactive Bladder

ADRB3 Approved 2020
APTIOM
CNS

Partial-Onset Seizures

Voltage-gated sodium channels Approved 2013
ORGOVYX
Oncology

Prostate Cancer

GnRH receptor Approved 2020

SUMITOMO PHARMA AM's Recent FDA Approvals

New NDA/BLA approvals for SUMITOMO PHARMA AM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

SUMITOMO PHARMA AM's Therapeutic Areas

SUMITOMO PHARMA AM's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%
1 drugs Phase 3: 5 Phase 2: 7 Phase 1: 24
Neurology 33%
1 drugs Phase 3: 7 Phase 2: 3 Phase 1: 2
Respiratory 12%
0 drugs Phase 3: 3 Phase 2: 1 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1
Metabolic 1%
0 drugs Phase 1: 1

SUMITOMO PHARMA AM's Top Competitors

SUMITOMO PHARMA AM's closest competitors by therapeutic-area and drug-target overlap include Merck, EISAI INC, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Oncology, Metabolic, Respiratory
EISAI INC big-pharma
Oncology, Neurology, Gastroenterology, Metabolic, Respiratory
AZURITY specialty
Oncology, Neurology, Metabolic, Respiratory
Johnson & Johnson big-pharma
Oncology, Gastroenterology, Metabolic
EMD SERONO biotech
Oncology, Neurology, Metabolic, Gastroenterology

SUMITOMO PHARMA AM Pipeline Snapshot

SUMITOMO PHARMA AM has 57 active clinical programs from ClinicalTrials.gov — 16 Phase 3, 12 Phase 2 and 29 Phase 1.

16
Phase 3
12
Phase 2
29
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MYFEMBREE leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 54/60 completed
  • • Speed: 23 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges